rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study
Status: Recruiting

The primary goal of the project is to test personalized medication experiments to inform decisions about future medication use. Our central hypothesis is that our intervention will lead to within subject increases in adolescent involvement in decision making and decreases in uncertainty about future medication use. The investigators view this open label trial as a pilot study to test the feasibility, acceptability, and preliminary efficacy of the medication experiment intervention and therefore warrants further testing in a future larger trial.

Eligibility:
- EligibilityCriteria: Inclusion Criteria: Participants for the study must meet all of the following criteria:  Consent: A parent or legal guardian must provide written informed consent Assent: Adolescents must provide written assent to participate in the study Ages 11-15 Treated for ADHD by pediatrician First prescribed ADHD medicine more than one year prior to enrollment Filled at least one prescription for a stimulant medication in the past year Uncertainty about continued ADHD medication use Only one child per household can participate in the study. For families who have more than one child who is potentially eligible, they may decide which of their children would be the best fit for the study.  Exclusion Criteria: Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria:  Do not have reliable access to the internet at their home or another location. Will not permit their child to access the internet for study related activities. Are not able or willing to send or receive text messages. - HealthyVolunteers: No - Gender: All - MinimumAge: 11 Years - MaximumAge: 15 Years - StdAgeList: Child
PEA: The Ability of Nurses To Recognize It (PEA: ANTRI)
Status: Recruiting

The Ability to recognize cardiac arrest is crucial in emergency situations and all health care professionals shloud be able to do so. The identification of pulseless electrical activity can be difficult even if the theoretical knowlegde of this state is well known. This research will be performed at the Simulation centre of Medical Faculty, Masaryk Unversity and it will be focused on nurses who will come to the simulation course. All the participants will get prelearning theoretical materials that will contain chapter about pulseless electrical activity and its recognition. In the beginning of the course they will be asked to fill up the questionnaire with four different pictures of patient´s monitor in cardiac arrest. It will be evaluated whether the pulseless electrical activity will be recognized.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Nurse or paramedic Participant of simulation course organised by Department of Simulation medicine, Faculty of medicine, Masaryk university  Exclusion Criteria:  No experience wiht monitoring patients by vital signs monitor - Gender: All - MinimumAge: 18 Years - MaximumAge: 99 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Participant of simulation course organised by Department of Simulation medicine, Faculty of medicine, Masaryk university - SamplingMethod: Non-Probability Sample
Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis
Status: Not yet recruiting

This study aims to observe the effects of keratinized mucosa width on peri-implant tissues by evaluating clinical and biochemical parameters. The main question it aims to answer is:

Would increasing the width of the keratinized mucosa with free gingival graft (FGG) in peri-implant mucositis be beneficial in terms of clinical periodontal parameters and peri-implant crevicular fluid levels of inflammatory cytokines compared to non-surgical therapy alone?

Our study consists of 4 groups:

Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm) (n=16), peri-implant mucositis group with sufficient keratinized mucosa (n=16), peri-implant mucositis group with insufficient keratinized mucosa (< 2mm) receiving only non-surgical treatment (n=16), peri-implant mucositis group with insufficient keratinized mucosa receiving FGG in addition to non-surgical treatment (n=16). Clinical and biochemical measurements will be recorded at the baseline, 1st month, 4th month and 7th month of the study. Peri-implant crevicular fluid samples will be collected at baseline, 1st month, 4th month and 7th month. IL-1β, RANKL, OPG levels, and RANKL/OPG ratio will be analyzed from collected samples.

Researchers will evaluate the possible benefits of FGG application in addition to non-surgical therapy by comparing the biochemical and clinical changes in areas with and without FGG application in the treatment of peri-implant mucositis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Individual dental implants with a fixed prosthetic restoration that has been functional for at least 1 year No systemic disease and medication use that may affect periodontal or peri-implanter tissues Not receiving periodontal treatment in the last 6 months Volunteering to participate in the study  Exclusion Criteria:  Prosthetic restorations with an excessive contour which do not allow peri-implant pocket measurement Being pregnant or breastfeeding, Autoimmune and/or inflammatory diseases of the oral cavity, Active periodontal disease Smokers (≥ 10 cigarettes per day) Improperly positioned implants - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Link Between Human Cytomegalovirus Gene Expression and Glutamate Level in Migraine;Relation to Vitamin D Deficiency
Status: Not yet recruiting

To correlate serum 25(OH)-vitamin D level with duration, frequency, and severity of migraine headache attacks
To evaluate the relationship between the serum level of vitamin D and other indices in patients with migraine.
To correlate the serum level of glutamate with gene expression of in migraine

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Selected patients fulfilled the criteria for diagnosis of migraine headache based on International Classification of Headache Disorders-II (ICHD-II) diagnostic criteria. The age of the selected patients ranged between 15 and 55 years of both sexes Able to give informed consent.  Exclusion Criteria:  b. Exclusion criteria:  presence of neurological disease other than migraine presence of other chronic medical conditions Participants in both groups were excluded from the study if they consumed vitamin D supplements in the preceding 3 months (any dose); or if they were taking medications that could affect vitamin D serum level such as glucocorticoids, thiazide diuretics, or statins. 4)patients refuse to participate in the study - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 15 Years - MaximumAge: 55 Years - StdAgeList: Child, Adult - StudyPopulation: Selected patients fulfilled the criteria for diagnosis of migraine headache based on International Classification of Headache Disorders-II (ICHD-II) diagnostic criteria.  And The age of the selected patients ranged between 15 and 55 years of both sexes - SamplingMethod: Non-Probability Sample
Injectable Platelet Rich Fibrin Post Tonsillectomy
Status: Not yet recruiting

To evaluate the effect of injectable Prf on healing, hemostasis and pain post tonsillectomy

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - Any patient indicated for tonsillectomy who will undergo either tonsillectomy alone or adenotonsillectomy  Exclusion Criteria:  children who expected to be unreliable in expressing pain due to behavioural pattern or disorder, developmental delayed, age less than 5yrs residence outside the city or patient unable to come for follow-up. children who have high anaesthetic risk or uncontrolled medical illness. bleeding diathesis. acute infection. unilateral tonsillectomy. Hemoglobin level<10mg/dl positive viral markers - HealthyVolunteers: No - Gender: All - MinimumAge: 5 Years - StdAgeList: Child, Adult, Older Adult
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
Status: Not yet recruiting

The main objective of this prospective study is to assess the clinical outcomes of platinum based chemotherapy cases either cisplatin or carboplatin according to BRCA status in neoadjuvant and recurrent ovarian cancer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age above 18 years, Pathologically proven ovarian cancer,epithelial origin. BRCA mutant/wild Recurrent cases who are eligible to anti-VEGF (Bevacizumab). Patients with clinical stages T1-T3c , N0-N1b, M0, and recurrent platinum sensitive cases. Patients with good renal and liver functions. No other malignancy (double malignancy). Performance status 0-2 according to ECOG performance status scale.  Exclusion Criteria:  Performance status 3-4 according to ECOG performance status scale. Patients refuse to receive chemotherapy, Patients not eligible to receive chemotherapy due to liver or renal impairment. - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Ovarian cancer patients - SamplingMethod: Non-Probability Sample
Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block
Status: Not yet recruiting

Effect of intravenous dexmedetomidine versus dexamethasone for management of repound pain after supraclavicular brachial plexus block.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients between 20_60 years old  Patients with ASA clinical status I/II Patients scheduled for peripheral nerve block for upper extremity surgery  Exclusion Criteria:  1) they refused to participate 2) had preexisting neuropathy of the surgical limb 3) hypersensitivity to amide anesthetic 4) significant pulmonary disease 5) coagulopathy 6) sepsis 7) infection at the block site 8) hypersensitivity to dexmedetomidine & dexamethasone - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 20 Years - MaximumAge: 60 Years - StdAgeList: Adult
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
Status: Not yet recruiting

BASiC-CIC Trial is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to investigate whether repurposing colchicine or a combination of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins will be effective as a prophylactic treatment for the prevention of chemotherapy-induced cardiomyopathy, reduction of major adverse cardiovascular events, and all-cause mortality.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Willing and able to provide written informed consent prior to performing study procedures. A cancer patient who is a candidate for a guideline-directed, anthracycline-based chemotherapy with or without the anti-HER2 trastuzumab. Baseline LVEF ≥ 50% without evident structural heart disease by pre-treatment echocardiographic examination.  Exclusion Criteria:  Critically ill Cancer patients who are admitted to ICU. Ischemic cardiomyopathy with LVEF ≤ 50%. Dilated cardiomyopathy with LVEF ≤ 50%. Advanced valvular heart disease (severe valvular affection in the form of stenosis or regurgitation). Systolic BP < 90 mmHg or diastolic BP < 60 mmHg. Liver cell failure. End-stage chronic kidney disease on regular dialysis. Pregnancy. Lactation. Chronic muscle diseases such as dermatomyositis, polymyositis, or muscular dystrophy. Acute trauma or burns within 2 weeks. History of allergy to the implemented drugs. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Status: Not yet recruiting

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Subject has completed the Week 78 of the Phase 3 core study (ALZ-801-AD301) while on study drug. Subject has a reliable study partner who has sufficient contact with the subject to be able to provide accurate information about the subject's cognitive and functional abilities.  Exclusion Criteria:  Significant worsening of medical conditions that may preclude completion of this study. Evidence of symptomatic or new moderate-severe radiologic ARIA at baseline. Has received (or plans to receive) amyloid antibodies since completing Phase 3 core study (ALZ-801-AD301). Subject taking any prohibited medications per protocol. - HealthyVolunteers: No - Gender: All - MinimumAge: 50 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Impact of Blocking the Glossopharyngeal Nerve on Gastroesophageal Reflux Disease
Status: Not yet recruiting

The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is:

• Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Meeting the diagnostic criteria for Gastroesophageal Reflux Disease. Age between 18 and 65 years. Confirmed tongue-pharyngeal nerve injury by electromyography. Esophageal manometry and barium swallow examination confirming the presence of pharyngeal dysphagia. Normal higher brain function, able to cooperate with treatment.  Exclusion Criteria:  Brain vascular disease diagnosed. Clinical assessment and swallowing videofluoroscopic examination revealing cognitive phase, oral preparatory phase, or oral phase disorders. Concurrent presence of other neurological disorders such as Alzheimer's disease, traumatic brain injury, Parkinson's disease. Esophageal obstruction and severe liver or kidney dysfunction Subjective unwillingness to undergo the treatment and presence of psychiatric abnormalities, etc. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL
Status: Not yet recruiting

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age > 18 years and < 80 years. Diagnosis of invasive breast cancer [ stage I-III ] and planned anthracycline treatment within 60 days. Signed Informed Consent to participate in the study.  Exclusion Criteria:  Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment. Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure. Left ventricular ejection fraction <50% at the time of the screening. Severe valvular heart disease. A history of clinically significant arrhythmia, including atrial fibrillation regardless of type (at discretion of the investigator). A history of stroke. Cardiomyopathy: congenital, post-inflammatory, toxic, infiltrative (e.g. amyloidosis, sarcoidosis, haemochromatosis), postnatal or hypertrophic. Pulmonary hypertension. Uncontrolled arterial pressure or systolic pressure <80 mmHg at screening at the discretion of the investigator. BMI>40 kg/m2. Diabetes type 1 or type 2. Pregnancy or breastfeeding. Taking another study drug or drugs from the group of SGLT2 inhibitors. eGFR <25 ml/min/1.73m2 according to CKD EPI Life expectancy <12 months or cancer disease stage IV according to the TNM classification. Any other condition which, in the opinion of the investigator, makes it impossible to fulfill the requirements for participation in this study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Risk of CKD in Diabetic Patients With MAFLD
Status: Not yet recruiting

This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for CKD in this population, contributing valuable insights to inform targeted interventions.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Type 2 diabetic patients Willing and agreed to be included in the study.  Exclusion Criteria:  Type 1 diabetic patients or non-diabetic patients. Patient with known glomerulonephritis. Patient with diagnosis of or clinical features that are suspicious for another systemic disease that commonly causes kidney disease (e.g., connective tissue disorders, HIV). Patient with evidence of alternative kidney disease like (Documented obstructive uropathy, etc.) Patient with history of kidney transplantation. Patient with end stage renal disease or on dialysis. Patients with active malignancy. Individuals with a history of hepatitis B surface antigen or hepatitis C antibody positivity. history of excessive alcohol consumption (⩾30 g/day in men and ⩾20 g/day in women) Decompensated liver cirrhosis. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population for this study comprises individuals diagnosed with type 2 diabetes mellitus either with or without MAFLD. The MAFLD group will encompass individuals meeting standardized diagnostic criteria for MAFLD and having a confirmed diagnosis of type 2 diabetes. Participants with comorbidities, such as viral hepatitis, cirrhosis, and cancers, will be excluded to ensure a focused study population. The chosen sample size of 300 individuals will allow for a robust examination of the prevalence of chronic kidney disease and associated risk factors within this specific cohort. - SamplingMethod: Non-Probability Sample
Use of Facility Ratings to Improve Satisfaction With Heath Care for Children
Status: Not yet recruiting

Despite increasing options for public and private health care providers in Laos, choosing a high-quality health provider or a facility is difficult because timely and reliable information about providers is not readily available. People rely on social networks or previous experiences to select providers. However, in Laos, only 28% describe their recent visit to a health care provider as high-quality suggesting that while there are increasing options for care, people may need support to find providers that meet their quality needs. Rapid adoption of mobile phones in Laos, particularly in urban areas, offer opportunities to enhance people's access to timely quality information about health care providers. We will use mobile phones to collect and disseminate quality information about providers - known to be valued by Laotians - to improve their access to quality care as well as their overall satisfaction with care.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All women 18 years of age and older and enrolled in Vientiane Multigenerational Birth Cohort (VITERBI) with at least one child less than two years old, able to read, have exclusive access to a mobile phone, have a WhatsApp account, understand and sign the ICF will be eligible to participate in the study. The eligibility criteria will be assessed using data collected from VITERBI. Ability to read will be tested using a script in Lao, "I use my mobile phone every day."  Exclusion Criteria:  Eligible women unwilling to sign informed consent, without exclusive access to a mobile phone, unable to read the test script, or unable operate a mobile phone will be excluded from the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
Status: Not yet recruiting

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Voluntarily sign the informed consent form (ICF); Male or female, 18 years old ≤ age ≤ 75 years old; Survival duration more than 3 months; ECOG score ≤ 1 point; Participants in Phase Ia (dose-escalation phase) are required to meet the following criteria: histologically or cytologically confirmed diagnosis of advanced malignant solid tumour; Participants in Phase Ib (dose-expansion phase) and Phase II are required to meet the following criteria: Histologically or cytologically confirmed specific type advanced malignant solid tumours; Adequate organ and bone marrow function.  Exclusion Criteria:  Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases; Other malignancies diagnosed within 5 years prior to the enrollment, except effectively treated malignant solid tumour (such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical cancer in situ, breast cancer in situ, etc.); History of hypertensive crisis or hypertensive encephalopathy; presence of uncontrolled hypertension. History of arterial thrombosis or deep vein thrombosis within 6 months prior to enrollmen; Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence; Received chemotherapy, immunotherapy, biologic therapy, or other anti-tumor treatments within 4 weeks before enrollment; Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study; Significant coagulopathy or other evident risk of bleeding; Major surgery or significant trauma within 4 weeks prior to enrollment; presence of unhealed skin wounds, surgical sites, trauma sites, severe mucosal ulcers, or fractures, or if the Investigator deems the participant unsuitable for the study; History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs; History of severe allergies, severe drug allergies (including unapproved investigational drugs), or known allergy to any component of the IMP; History of organ transplantation or stem cell transplantation; Pregnant or breastfeeding female; women of childbearing potential with positive pregnancy test within 7 days before the enrollment; participants (including males of childbearing potential and their female partners, and females of childbearing potential and their male partners) unwilling to use medically recognized effective contraception during the study and for 6 months after treatment ends. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult